Evaluation of Circulating Tumor DNA Across Multiple Resectable Solid Tumors to Assess Its Association with Multi-Biomarker Profiles and Recurrence Risk

Evaluation of Circulating Tumor DNA Across Multiple Resectable Solid Tumors to Assess Its Association with Multi-Biomarker Profiles and Recurrence Risk - Pan-Latitude Monstar-3

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061889

Enrollment

800

Registered

2026-06-15

Start date

2026-06-17

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, gastric cancer, esophageal cancer, liver cancer, biliary truct cancer, pancreatic cancer, urothelial cancer, kidney cancer, endometrial cancer, cervical cancer, head and neck cancer, skin cancer, bone and soft tissue sarcoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with breast cancer, gastric cancer, esophageal cancer, liver cancer, biliary truct cancer, pancreatic cancer, urothelial cancer, kidney cancer, endometrial cancer, cervical cancer, head and neck cancer, skin cancer, bone and soft tissue sarcoma who were enrolled in the MONSTAR-SCREEN-3 trial (Cohort B) and received curative treatment

Exclusion criteria

Exclusion criteria: 1.Cases with missing data required for this study. 2.Cases deemed inappropriate for enrollment in this study by the principal investigator. 3.Cases of withdrawal of consent or refusal of secondary use of specimens and/or data.

Design outcomes

Primary

Measure	Time frame
The association between ctDNA MRD status and recurrence (Disease-free survival:DFS)	—

Secondary

Measure	Time frame
Association between ctDNA status and the efficacy of adjuvant therapy Overall survival (OS) ctDNA positivity Association between ctDNA status and clinicopathological/molecular characteristics, etc.	—

Countries

Japan

Contacts

Public ContactTadayoshi Hashimoto

National Cancer Center Hospital East Division for the Promotion of Drug and Diagnostic Development

tadhashi@east.ncc.go.jp04-7133-1111

Outcome results